Market size, growth to 2033 and clinical trials, side by side.
The US is the bigger Mood and Stress Supplements market: $4.4 Bn against $844 Mn in 2023, about 5.2 times as large.
China grows faster: 9.6% a year, against 6.1%. The gap still grows from $3.6 Bn to $5.9 Bn by 2033.
Clinical research: 64 active trials in the US, 3 in China.
| Measure | ||
|---|---|---|
| Market size, 2023 | $4.4 Bn | $844 Mn |
| Market size, 2033 projected | $8 Bn | $2.1 Bn |
| Growth a year (CAGR) | 6.1% | 9.6% |
| Money added, 2023–2033 | $3.6 Bn | $1.3 Bn |
| Share of the world market | 42% | 8% |
| Size rank of 24 countries | #1 | #2 |
| Market per person, 2023 | $13 | $0.60 |
| Active clinical trials | 64 | 3 |
| Full report | US report | China report |
US China · values between 2023 and 2033 are projected from the 2023 size and the CAGR.
The US is the bigger Mood and Stress Supplements market: $4.4 Bn against $844 Mn in 2023, about 5.2 times as large.
China grows faster: 9.6% a year, against 6.1%. The gap still grows from $3.6 Bn to $5.9 Bn by 2033.
Sources: market size and growth: Acuitas Health Analytics research (2023 base year, forecasts to 2033). Trials: ClinicalTrials.gov (fetched 10 Nov 2026); found by search words, so counts are a guide. Population: World Bank.